12-O-Tetradecanoylphorbol-13-acetate Promotes Breast Cancer Cell Motility by Increasing S100A14 Level in a Kruppel-like Transcription Factor 4 (KLF4)-dependent Manner

Abstract

Background:The transcriptional regulation of S100A14 and its underlying mechanism have not been fully elucidated. Results: The activation of S100A14 promoter by KLF4 mediates its up-regulation upon TPA stimulation. Conclusion: S100A14 partly mediates TPA-induced cell motility in a KLF4-dependent manner. Significance: KLF4 plays a significant and previously unrecognized role in regulation of S100A14.

Krüppel-like Factor 4 Promotes Esophageal Squamous Cell Carcinoma Differentiation by Up-regulating Keratin 13 Expression

“…KLF5 played an essential role in the differentiation and homeostasis of epithelial cells, smooth muscle cells and adipocytes by regulating the expression of KRT5, SM22␣, peroxisome proliferator-activated receptor ␥ and others (39,40). Our previous results showed that KLF4 could bind directly to the promoter of S100A14 and activate its transcription, which modulated the terminal differentiation in esophageal cancer (26,28). cDNA microarray analysis also revealed a group of KRT genes, especially those located in a specific region on chromosome 12 could be induced by KLF4 (10).…”

“…Western Blot Analysis-Western blots were performed as described previously (26). Antibodies used were anti-KLF4 and anti-KRT13.…”

“…Chromatin Immunoprecipitation Assay (ChIP)-ChIP was performed as described previously (26). The antibodies used were anti-KLF4 and anti-tubulin (Sigma).…”

Inhibitor of Differentiation/DNA Binding 1 (ID1) Inhibits Etoposide-induced Apoptosis in a c-Jun/c-Fos-dependent Manner

“…Western Blot Analysis-Western blot was performed as described previously (29). The following antibodies were used: ID1, cleaved caspase 3, PARP, p53, c-Jun, and c-Fos (Santa Cruz, Delaware, CA) and ␤-actin (Sigma-Aldrich).…”

“…Chromatin Immunoprecipitation Assay and Luciferase AssayThe luciferase assay and ChIP was performed as described previously (29). The antibodies against c-Jun and c-Fos were from Beijing Golden Bridge Biotechnology Company.…”